Darya Kamkalova

Daya Ventures is the world’s first Femtech Venture Studio, dedicated exclusively to transforming women’s health by building and scaling innovative startups. Since 2022, we’ve launched and accelerated a portfolio of women-led companies tackling critical health challenges with cutting-edge technology. Our venture studio model takes ideas from concept to market, offering founders the tailored resources, expert guidance, and extensive network they need to succeed. Operating within a $1 trillion market, Daya isn’t just driving change — we’re shaping the future of healthcare for women. Our mission is bold yet clear: to close the gender health gap by creating high-growth, high-impact startups.

Members-only offline social network

ammi provides easy access to multi-disciplinary expertise to expectant and new parents. The service currently offers weekly virtual workshops with multi-disciplinary experts in infant physical and mental health, parental mental health and maternal physical health. From October 2022 to February 2023, we have approx. 300 parents signed up to our growing community. We are also developing an proprietary evidence based digital program/tool to optimise the well-being of perinatal parents, with an aim to optimise their mental wellbeing during this major life transition. The team consists of advisors, practitioners and clinicians based in in the UK, US and New Zealand, and technology and evaluation partners based in the U.K. Sign up for our current workshops here: https://www.eventbrite.com/cc/ammi-1348439

The journey to bring a new drug from concept to market takes over 10 years, costs 2.5B dollars, and faces a failure rate of over 90%. Target identification is the first and most crucial step in drug discovery, influencing the probability of success at every subsequent step of drug development. We have hundreds of thousands of potential targets and their combinations to choose from, but determining the right one for a specific disease remains a challenge. To address this, we tap into the primary source of data: academic researchers. Elnora AI is revolutionizing drug discovery by harnessing the power of AI and the academic research community. This approach accelerates the R&D process, makes it faster, more cost-effective, and more reliable by avoiding repeated mistakes. Our platform collects ML-readable, detailed data on experiment conditions and outcomes. This includes failed experiments, repeated trials under various conditions, and studies conducted worldwide. We also extract data from publicly available datasets and scientific papers, integrating it with researchers raw data. Subsequently, we feed this comprehensive dataset into our AI models to identify the fastest, most efficient path to groundbreaking discoveries. Elnora can replicate the process of finding novel drug targets likely to succeed in subsequent phases of development. By combining public and proprietary datasets, we can predict success scores for each s in the identification of a viable drug target. As a techbio company guided by triple bottom line principles and driven by a mission to have a real impact, we are leveraging the Elnora platform ourselves to chart a new course in antiviral drug discovery. While thousands of viruses threaten human health, the antiviral drug solutions are limited. Our unique approach focuses on host cells rather than directly targeting viruses, offering potential resistance to viral mutations and broad-spectrum efficacy against a range of viral strains.

WHU – Otto Beisheim School of Management is a mainly privately funded Business School based in Vallendar/Koblenz and in Düsseldorf. It is a leading Business School in Germany and is continuously ranked among the top Business Schools in Europe. The range of courses includes a Bachelor Program, the Master in Management and Master in Finance Programs, a Full-Time MBA Program, a Part-Time MBA Program and the Kellogg-WHU Executive MBA Program. In addition, WHU offers open programs as well as customized programs for management which are tailored to the needs of the particular enterprise. For more information please visit www.whu.edu. IMPRINT: Address: WHU - Otto Beisheim School of Management Burgplatz 2 D-56179 Vallendar Germany Responsible Body: WHU Foundation Authorized Representative: Prof. Dr. Markus Rudolf, Dean Contact: Fon +49(0)261-65 09-0 Fax +49(0)261-65 09-509 whu(at)whu.edu Value added tax identification number: DE 148 733 174 Edited in accordance with §55 par. 2 of the Interstate Broadcasting Treaty (RStV) by: Marketing

Daya Ventures is the world’s first Femtech Venture Studio, dedicated exclusively to transforming women’s health by building and scaling innovative startups. Since 2022, we’ve launched and accelerated a portfolio of women-led companies tackling critical health challenges with cutting-edge technology. Our venture studio model takes ideas from concept to market, offering founders the tailored resources, expert guidance, and extensive network they need to succeed. Operating within a $1 trillion market, Daya isn’t just driving change — we’re shaping the future of healthcare for women. Our mission is bold yet clear: to close the gender health gap by creating high-growth, high-impact startups.

Escape the linear path. Build a digital business that fits your life, not someone else’s script. Off Script is a newsletter and network for misfits, adventurers, and brave builders who are done with cookie-cutter careers and life trajectories.

Pre-seed investors back the team. At seed, you must convince them with numbers. We build metrics VCs want to see. Exceed your growth targets and close your seed round. Fast.

Visual credit: Vecteezy.com